Nature Reviews Cancer最新文献_第7页

The rhythm of the night 夜的节奏

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-06-25 DOI: 10.1038/s41568-024-00717-3

Gabrielle Brewer

引用次数: 0

The road less travelled 少有人走的路

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-06-21 DOI: 10.1038/s41568-024-00720-8

引用次数: 0

Why do patients with cancer die? 癌症患者为什么会死亡？

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-06-19 DOI: 10.1038/s41568-024-00708-4

Adrienne Boire, Katy Burke, Thomas R. Cox, Theresa Guise, Mariam Jamal-Hanjani, Tobias Janowitz, Rosandra Kaplan, Rebecca Lee, Charles Swanton, Matthew G. Vander Heiden, Erik Sahai

{"title":"Why do patients with cancer die?","authors":"Adrienne Boire, Katy Burke, Thomas R. Cox, Theresa Guise, Mariam Jamal-Hanjani, Tobias Janowitz, Rosandra Kaplan, Rebecca Lee, Charles Swanton, Matthew G. Vander Heiden, Erik Sahai","doi":"10.1038/s41568-024-00708-4","DOIUrl":"10.1038/s41568-024-00708-4","url":null,"abstract":"Cancer is a major cause of global mortality, both in affluent countries and increasingly in developing nations. Many patients with cancer experience reduced life expectancy and have metastatic disease at the time of death. However, the more precise causes of mortality and patient deterioration before death remain poorly understood. This scarcity of information, particularly the lack of mechanistic insights, presents a challenge for the development of novel treatment strategies to improve the quality of, and potentially extend, life for patients with late-stage cancer. In addition, earlier deployment of existing strategies to prolong quality of life is highly desirable. In this Roadmap, we review the proximal causes of mortality in patients with cancer and discuss current knowledge about the interconnections between mechanisms that contribute to mortality, before finally proposing new and improved avenues for data collection, research and the development of treatment strategies that may improve quality of life for patients. In this Roadmap, Boire et al. consider the immediate causes of mortality in patients with cancer, a topic not often considered in either preclinical or clinical research, and provide recommendations for how we can stimulate research to advance our mechanistic understanding of these causes with a long-term view to improving the quality of life for patients with late-stage cancer.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 8","pages":"578-589"},"PeriodicalIF":72.5,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141425211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The importance of 3D fibre architecture in cancer and implications for biomaterial model design 三维纤维结构在癌症中的重要性及其对生物材料模型设计的影响

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-06-17 DOI: 10.1038/s41568-024-00704-8

J. C. Ashworth, T. R. Cox

{"title":"The importance of 3D fibre architecture in cancer and implications for biomaterial model design","authors":"J. C. Ashworth, T. R. Cox","doi":"10.1038/s41568-024-00704-8","DOIUrl":"10.1038/s41568-024-00704-8","url":null,"abstract":"The need for improved prediction of clinical response is driving the development of cancer models with enhanced physiological relevance. A new concept of ‘precision biomaterials’ is emerging, encompassing patient-mimetic biomaterial models that seek to accurately detect, treat and model cancer by faithfully recapitulating key microenvironmental characteristics. Despite recent advances allowing tissue-mimetic stiffness and molecular composition to be replicated in vitro, approaches for reproducing the 3D fibre architectures found in tumour extracellular matrix (ECM) remain relatively unexplored. Although the precise influences of patient-specific fibre architecture are unclear, we summarize the known roles of tumour fibre architecture, underlining their implications in cell–matrix interactions and ultimately clinical outcome. We then explore the challenges in reproducing tissue-specific 3D fibre architecture(s) in vitro, highlighting relevant biomaterial fabrication techniques and their benefits and limitations. Finally, we discuss imaging and image analysis techniques (focussing on collagen I-optimized approaches) that could hold the key to mapping tumour-specific ECM into high-fidelity biomaterial models. We anticipate that an interdisciplinary approach, combining materials science, cancer research and image analysis, will elucidate the role of 3D fibre architecture in tumour development, leading to the next generation of patient-mimetic models for mechanistic studies and drug discovery. Although there has been increasing interest in developing models that mimic the tumour microenvironment (TME), these models often fail to replicate the complex 3D fibre architectures observed in tumours. Here, Ashworth and Cox address this, discuss the current design and fabrication challenges, and outline state-of-the-art biomaterial technologies useful for recreating tissue-specific 3D architectures in vitro.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 7","pages":"461-479"},"PeriodicalIF":72.5,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141333528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploiting temporal aspects of cancer immunotherapy 利用癌症免疫疗法的时间因素

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-06-17 DOI: 10.1038/s41568-024-00699-2

Rachael M. Zemek, Valsamo Anagnostou, Inês Pires da Silva, Georgina V. Long, Willem Joost Lesterhuis

{"title":"Exploiting temporal aspects of cancer immunotherapy","authors":"Rachael M. Zemek, Valsamo Anagnostou, Inês Pires da Silva, Georgina V. Long, Willem Joost Lesterhuis","doi":"10.1038/s41568-024-00699-2","DOIUrl":"10.1038/s41568-024-00699-2","url":null,"abstract":"Many mechanisms underlying an effective immunotherapy-induced antitumour response are transient and critically time dependent. This is equally true for several immunological events in the tumour microenvironment induced by other cancer treatments. Immune checkpoint therapy (ICT) has proven to be very effective in the treatment of some cancers, but unfortunately, with many cancer types, most patients do not experience a benefit. To improve outcomes, a multitude of clinical trials are testing combinations of ICT with various other treatment modalities. Ideally, those combination treatments should take time-dependent immunological events into account. Recent studies have started to map the dynamic cellular and molecular changes that occur during treatment with ICT, in the tumour and systemically. Here, we overlay the dynamic ICT response with the therapeutic response following surgery, radiotherapy, chemotherapy and targeted therapies. We propose that by combining treatments in a time-conscious manner, we may optimally exploit the interactions between the individual therapies. The tumour immune microenvironment greatly affects responses to immune checkpoint therapies. In this Perspective, Zemek et al. explore the dynamic changes in response to both immunotherapy and conventional treatment and advocate for strategic combination therapies over time to enhance antitumour immune responses.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 7","pages":"480-497"},"PeriodicalIF":72.5,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141334407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The path to leptomeningeal metastasis 脑转移之路

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-06-13 DOI: 10.1038/s41568-024-00700-y

Jan Remsik, Adrienne Boire

{"title":"The path to leptomeningeal metastasis","authors":"Jan Remsik, Adrienne Boire","doi":"10.1038/s41568-024-00700-y","DOIUrl":"10.1038/s41568-024-00700-y","url":null,"abstract":"The leptomeninges, the cerebrospinal-fluid-filled tissues surrounding the central nervous system, play host to various pathologies including infection, neuroinflammation and malignancy. Spread of systemic cancer into this space, termed leptomeningeal metastasis, occurs in 5–10% of patients with solid tumours and portends a bleak clinical prognosis. Previous, predominantly descriptive, clinical studies have provided few insights. Recent development of preclinical leptomeningeal metastasis models, alongside genomic, transcriptomic and proteomic sequencing efforts, has provided groundwork for mechanistic understanding and identification of long-needed therapeutic targets. Although previously understood as an anatomically isolated compartment, the leptomeninges are increasingly appreciated as a major conduit of communication between the systemic circulation and the central nervous system. Despite the unique nature of the leptomeningeal microenvironment, the general principles of metastasis hold true: cells metastasizing to the leptomeninges must gain access to the new environment, survive within the space and evade the immune system. The study of leptomeningeal metastasis has the potential to uncover novel site-specific metastatic principles and illuminate the physiology of the leptomeningeal space. In this Review, we provide a biology-focused overview of how metastatic cells reach the leptomeninges, thrive in this nutritionally sparse environment and evade the detection of the omnipresent immune system. Metastasis to the leptomeninges causes substantial neurological morbidity and mortality. Owing to the lack of mechanistic studies in this area, patients still face a bleak clinical prognosis. In this Review, Remsik and Boire provide a biology-focused overview of recent developments enabled by preclinical models and omics analyses and outline the need for further mechanistic research on leptomeningeal metastasis.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 7","pages":"448-460"},"PeriodicalIF":72.5,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141315648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours 确定实体瘤免疫检查点抑制剂的临床有用生物标记物

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-06-12 DOI: 10.1038/s41568-024-00705-7

Ashley M. Holder, Aikaterini Dedeilia, Kailan Sierra-Davidson, Sonia Cohen, David Liu, Aparna Parikh, Genevieve M. Boland

{"title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","authors":"Ashley M. Holder, Aikaterini Dedeilia, Kailan Sierra-Davidson, Sonia Cohen, David Liu, Aparna Parikh, Genevieve M. Boland","doi":"10.1038/s41568-024-00705-7","DOIUrl":"10.1038/s41568-024-00705-7","url":null,"abstract":"Although more than a decade has passed since the approval of immune checkpoint inhibitors (ICIs) for the treatment of melanoma and non-small-cell lung, breast and gastrointestinal cancers, many patients still show limited response. US Food and Drug Administration (FDA)-approved biomarkers include programmed cell death 1 ligand 1 (PDL1) expression, microsatellite status (that is, microsatellite instability-high (MSI-H)) and tumour mutational burden (TMB), but these have limited utility and/or lack standardized testing approaches for pan-cancer applications. Tissue-based analytes (such as tumour gene signatures, tumour antigen presentation or tumour microenvironment profiles) show a correlation with immune response, but equally, these demonstrate limited efficacy, as they represent a single time point and a single spatial assessment. Patient heterogeneity as well as inter- and intra-tumoural differences across different tissue sites and time points represent substantial challenges for static biomarkers. However, dynamic biomarkers such as longitudinal biopsies or novel, less-invasive markers such as blood-based biomarkers, radiomics and the gut microbiome show increasing potential for the dynamic identification of ICI response, and patient-tailored predictors identified through neoadjuvant trials or novel ex vivo tumour models can help to personalize treatment. In this Perspective, we critically assess the multiple new static, dynamic and patient-specific biomarkers, highlight the newest consortia and trial efforts, and provide recommendations for future clinical trials to make meaningful steps forwards in the field. In this Perspective, Holder et al. discuss the limitations of current predictive biomarkers of response to immune checkpoint inhibitors and the need to further explore static, dynamic and patient-specific biomarkers using novel tools, such as machine learning and consortia-level initiatives.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 7","pages":"498-512"},"PeriodicalIF":72.5,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141308952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eliminating false positives 消除误报

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-06-10 DOI: 10.1038/s41568-024-00716-4

Daniela Senft

引用次数: 0

Charting spatially resolved cell states with CytoSPACE 利用 CytoSPACE 绘制空间解析细胞状态图

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-06-10 DOI: 10.1038/s41568-024-00713-7

Erin L. Brown

引用次数: 0

Bone voyage: immune crosstalk sets sail 骨骼之旅：免疫串联起航。

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-06-04 DOI: 10.1038/s41568-024-00712-8

Gabrielle Brewer

引用次数: 0